The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic leukemias and down-regulated with disease progression

被引:30
作者
Casanova, B
de la Fuente, MT
Garcia-Gila, M
Sanz, L
Silva, A
Garcia-Marco, JA
Garcia-Pardo, A
机构
[1] CSIC, Ctr Invest Biol, Dept Inmunol, Madrid, Spain
[2] Hosp Univ Clin Puerta Hierro, Hematol Serv, Madrid, Spain
关键词
RARRES3; B-chronic lymphocytic leukemia; mRNA differential display; tumor suppressor gene; lymphoproliferative disorders;
D O I
10.1038/sj.leu.2402243
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The molecular pathogenesis of B cell chronic lymphocytic leukemia (B-CLL), the most common form of leukemia, remains unknown. We have used the mRNA differential display technique to analyze genes that may be involved in the development/progression of B-CLL. We have identified the tumor suppressor retinoic acid receptor responder 3 (RARRES3) as a B-CLL-related gene. RARRES3 maps to chromosome band 11q23, a region frequently deleted in lymphoproliferative disorders. To assess the potential involvement of RARRES3 in leukemogenesis, we examined 24 cases of B-CLL, 10 of acute lymphocytic leukemia (ALL) and five related cell lines by RT-PCR and sequence analyses. We report a correlation between RARRES3 down-regulation and B-CLL progression. We also found decreased RARRES3 gene levels in ALL cases and in the five cell lines studied. We did not find mutations in any of the leukemia samples assayed, including those with 11q23 deletion. These results indicate that RARRES3 may play a role in B-CLL progression.
引用
收藏
页码:1521 / 1526
页数:6
相关论文
共 37 条
[1]   Frequent methylation silencing of p15INK4b (MTS2) and p16INK4a (MTS1) in B-cell and T-cell lymphomas [J].
Baur, AS ;
Shaw, P ;
Burri, N ;
Delacrétaz, F ;
Bosman, FT ;
Chaubert, P .
BLOOD, 1999, 94 (05) :1773-1781
[2]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[3]  
2-V
[4]  
Bullrich F, 1999, CANCER RES, V59, P24
[5]  
Corcoran MM, 2000, BLOOD, V96, p702A
[6]   p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis [J].
Cordone, I ;
Masi, S ;
Mauro, FR ;
Soddu, S ;
Morsilli, O ;
Valentini, T ;
Vegna, ML ;
Guglielmi, C ;
Mancini, F ;
Giuliacci, S ;
Sacchi, A ;
Mandelli, F ;
Foa, R .
BLOOD, 1998, 91 (11) :4342-4349
[7]  
Corn PG, 1999, CANCER RES, V59, P3352
[8]   Fibronectin interaction with α4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia:: correlation with Bcl-2 and Bax [J].
de la Fuente, MT ;
Casanova, B ;
Garcia-Gila, M ;
Silva, A ;
Garcia-Pardo, A .
LEUKEMIA, 1999, 13 (02) :266-274
[9]   Identification and characterization of a retinoid-induced class II tumor suppressor growth regulatory gene [J].
DiSepio, D ;
Ghosn, C ;
Eckert, RL ;
Deucher, A ;
Robinson, N ;
Duvic, M ;
Chandraratna, RAS ;
Nagpal, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14811-14815
[10]   Chromosome aberrations in B-cell chronic lymphocytic leukemia:: reassessment based on molecular cytogenetic analysis [J].
Döhner, H ;
Stilgenbauer, S ;
Döhner, K ;
Bentz, M ;
Lichter, P .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (02) :266-281